News & Media

News

March 1, 2023

Andelyn Biosciences Board of Directors Announce New CEO

Blog

February 8, 2022

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

Gene therapies offer an unprecedented ability to treat — and even cure — genetic diseases, and their potential spanning diverse...

Media Release

January 13, 2022

FDA Accepts GMP Plasmid DMF and Capacity Expansion Enabling Andelyn Biosciences to Offer Faster Gene Therapy Development

COLUMBUS, OH, January 13, 2022 – Andelyn Biosciences, a pioneering cell and gene therapy CDMO born out of Nationwide Children’s Hospital, today...

News

November 22, 2021

Nationwide Children’s Spinoff Andelyn Biosciences to Open New Lab in Dublin

Andelyn Biosciences has set its sights on Dublin for one of two new labs for the gene therapy company.

Blog

November 11, 2021

Leveraging Partnerships and a Unique History to Address Supply Chain and Capacity Challenges in Gene Therapy Manufacturing

Andelyn Biosciences has established a unique network of industry experts across the entire development and commercialization spectrum. In addition to...

Blog

October 22, 2021

Coping with a Talent Shortage and Talent War in Cell and Gene Therapy

Andelyn Biosciences is building the best cell and gene therapy team in spite of a talent shortage and competitive talent...

News

September 30, 2021

Gene therapy manufacturer Andelyn adds lab in Dublin as construction continues in OSU Innovation District

Andelyn Biosciences Inc. is adding a second laboratory in Dublin, and will move into its headquarters in Ohio State University's Innovation District before construction is complete.

Blog

September 23, 2021

Navigating Analytical Requirements for GMP Viral Vectors

The analytical requirements for viral vectors used to deliver gene therapies are complex and constantly evolving. The keys to success,...

Blog

September 16, 2021

Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing

The number of gene therapy candidates in development is growing rapidly, with many advancing toward late-stage trials. The majority of...

Media Release

August 25, 2021

Andelyn Biosciences Selects TetraScience as a Strategic Partner for Innovation in Therapeutics Development and Manufacturing

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers.

Blog

August 23, 2021

Andelyn Biosciences: A New CDMO with Roots in Gene Therapy Research Set to Drive Key Manufacturing Advances

Abstract: Andelyn Biosciences, a full-spectrum gene therapy CDMO organization that supports clients from preclinical studies through phase III trials, originally...

Connect Here With Our Business Team